Healthcare Capital Acquisition - HCAC Stock Price Target and Predictions

  • Consensus Rating: Sell
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 1
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$10.15
▲ +0.02 (0.20%)

This chart shows the closing price for HCAC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Healthcare Capital Acquisition Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HCAC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HCAC

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Healthcare Capital Acquisition in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $10.15.

This chart shows the closing price for HCAC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Sell

The current consensus among 1 polled investment analysts is to sell stock in Healthcare Capital Acquisition.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/18/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/17/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/15/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/13/2026
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/13/2026
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/12/2026
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
9/10/2026
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
10/10/2026

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/2/2026Weiss RatingsUpgradeSell (E+) ➝ Sell (D-)
8/24/2026Weiss RatingsInitiated CoverageSell (E+)
(Data available from 10/10/2021 forward)

News Sentiment Rating

0.93 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/14/2026
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/13/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/13/2026
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/12/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/12/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/11/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/10/2026
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/10/2026

Current Sentiment

  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Healthcare Capital Acquisition

We are a blank check company newly incorporated as a Cayman Islands exempted company for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities, which we refer to throughout this prospectus as our initial business combination. We have not selected any business combination target, and we have not, nor has anyone on our behalf, initiated any substantive discussions, directly or indirectly, with any business combination target. While we may pursue an initial business combination target in any industry or geographical location, we believe that the technology, critical materials, and energy sectors offer particularly compelling business combination opportunities for our team. Specifically, we are interested in companies implementing transformative technologies to further advance the changing landscapes within global connectivity, sustainability, and continued infrastructure development. We believe significant opportunities exist in acquiring and merging with high-growth companies leading the charge in technology, critical materials, and energy. Our focus lies in identifying companies with disruptive solutions that demonstrate strong growth potential. We aim to accelerate their growth by providing them with operational and strategic expertise, access to new capital, and a pathway to public markets. Through active engagement and ongoing support, we strive to cultivate sustainable growth and deliver strong long-term returns for our investors. Our extensive sourcing network includes (i) business founders, owners and senior management contacts, (ii) marquee global funds including sovereign wealth funds and pension fund and a broad base of institutional investors, (iii) private equity, financial investors and other sponsors of private businesses and (iv) industry professionals, including investment banking, legal, accounting and other industry focused experts. We believe our extensive network within our focus industries — primarily technology, as well as other areas including critical materials and energy — provides access to highly attractive investment opportunities. Our management team’s combined experience and expertise offer unique insights into evaluating potential targets across numerous sectors. We plan to target businesses at inflection points in their life cycles, believing they can significantly benefit from our strategic guidance, capital infusion, and expertise. Our goal is to accelerate their business development, enhance their prospects, and unlock their full value. We are confident in our management team’s ability to significantly enhance the value of a target company. Their expertise spans strategic planning, financial planning, commercialization, capital markets navigation, and public company operations. This deep operational experience, coupled with our team’s proven track record in the public markets, positions us to deliver an attractive risk-adjusted return profile through our active involvement and comprehensive due diligence. Alex Bono, our chief executive officer and director is a seasoned digital transformation leader with over 25 years of experience driving innovation in technology, AI, blockchain, and e-commerce. Our executive offices are located in Singapore.
Read More

Today's Range

Now: $10.15
Low: $10.15
High: $10.16

50 Day Range

MA: $10.10
Low: $10.07
High: $10.15

52 Week Range

Now: $10.15
Low: $9.91
High: $10.16

Volume

215,717 shs

Average Volume

91,713 shs

Market Capitalization

$378.67 million

P/E Ratio

203.00

Dividend Yield

N/A

Beta

0.41

Frequently Asked Questions

What sell-side analysts currently cover shares of Healthcare Capital Acquisition?

The following Wall Street analysts have issued reports on Healthcare Capital Acquisition in the last twelve months: Weiss Ratings.
View the latest analyst ratings for HCAC.

What is the current price target for Healthcare Capital Acquisition?

0 Wall Street analysts have set twelve-month price targets for Healthcare Capital Acquisition in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Healthcare Capital Acquisition in the next year.
View the latest price targets for HCAC.

What is the current consensus analyst rating for Healthcare Capital Acquisition?

Healthcare Capital Acquisition currently has 1 sell rating from Wall Street analysts. The stock has a consensus analyst rating of "Sell." A "sell" rating indicates that analysts believe HCAC will underperform the market and that investors should sell shares of Healthcare Capital Acquisition.
View the latest ratings for HCAC.

How do I contact Healthcare Capital Acquisition's investor relations team?

Healthcare Capital Acquisition's physical mailing address is 1 North Bridge Road, Singapore, CE, 179094. The company's listed phone number is (284) 852-4333. The official website for Healthcare Capital Acquisition is www.hcacq.com. Learn More about contacing Healthcare Capital Acquisition investor relations.